Article

The Effect of Soy Phytoestrogen Supplementation on Thyroid Status and Cardiovascular Risk Markers in Patients with Subclinical Hypothyroidism: A Randomized, Double-Blind, Crossover Study

Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU3 2JZ, United Kingdom.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 02/2011; 96(5):1442-9. DOI: 10.1210/jc.2010-2255
Source: PubMed

ABSTRACT There is concern whether soy phytoestrogens may affect thyroid function. If true, soy phytoestrogens may be expected to have a greater impact in subjects with subclinical hypothyroidism.
The primary aim was to determine the effect of soy phytoestrogen supplementation on thyroid function, with a secondary aim of assessing the effects on cardiovascular risk indices in patients with subclinical hypothyroidism.
We conducted a randomized, double-blind, crossover study in a tertiary care setting.
Sixty patients with subclinical hypothyroidism participated in the study.
Patients were randomly assigned to either low-dose phytoestrogen (30 g soy protein with 2 mg phytoestrogens, representative of a Western diet) or high-dose phytoestrogen (30 g soy protein with 16 mg phytoestrogens, representative of a vegetarian diet) supplementation for 8 wk, then crossed over after an 8-wk washout period.
The primary outcome was progression to overt hypothyroidism, with secondary outcome measures of blood pressure, insulin resistance, lipids, and highly sensitive C-reactive protein (hsCRP).
Six female patients in the study progressed into overt hypothyroidism with a standardized rate ratio of 3.6 (95% confidence interval, 1.9, 6.2) after 16-mg phytoestrogen supplementation. Both systolic and diastolic blood pressure decreased with 16 mg phytoestrogens, whereas systolic pressure alone decreased with 2 mg phytoestrogens. Insulin resistance (homeostasis model assessment of insulin resistance, 3.5 ± 0.09 vs. 2.6 ± 0.08; P < 0.02) and hsCRP (4.9 ± 0.04 vs. 3.9 ± 0.03; P < 0.01) decreased with 16 mg phytoestrogens. Lipid profile remained unchanged.
There is a 3-fold increased risk of developing overt hypothyroidism with dietary supplementation of 16 mg soy phytoestrogens with subclinical hypothyroidism. However, 16-mg soy phytoestrogen supplementation significantly reduces the insulin resistance, hsCRP, and blood pressure in these patients.

1 Follower
 · 
93 Views
 · 
0 Downloads
  • Source
    • "Results of clinical studies with healthy individuals were inconsistent, reporting that isoflavones have significant, mild or no effect on thyroid function (Bitto et al., 2010). However, in a recent randomized double-blind crossover study with subclinically hypothyroid patients receiving soybased phytoestrogens containing G and D for 8 weeks, six of sixty patients developed overt hypothyroidism indicating interference of soy isoflavones with the thyroid hormone axis (Sathyapalan et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that genistein (G) and daidzein (D) administered subcutaneously (10mg/kg) induce changes in the angio-follicular units of the thyroid gland, reduce concentration of total thyroid hormones (TH) and increase thyrotropin (TSH) in serum of orchidectomized middle-aged (16-month-old) rats. To further investigate these effects, we now examined expression levels of the thyroglobulin (Tg), thyroperoxidase (Tpo), vascular endothelial growth factor A (Vegfa) and deiodinase type 1 (Dio 1) genes in the thyroid; in the pituitary, genes involved in TH feedback control (Tsh β, Dio 1, Dio 2, Trh receptor); and in the liver and kidney, expression of T3-activated genes Dio 1 and Spot 14, as well as transthyretin (Ttr), by quantitative real-time PCR. We also analyzed TPO-immunopositivity and immunofluorescence of T4 bound to Tg, determined thyroid T4 levels and measured deiodinase enzyme activities in examined organs. Decreased expression of Tg and Tpo genes (p<0.05) correlated with immunohistochemical staining results, and together with decreased serum total T4 levels, indicate decreased Tg and TH synthesis following treatments with both isoflavones. However, expression of Spot 14 (p<0.05) gene in liver and kidney were up-regulated, and liver Dio 1 expression and activity (p<0.05) increased. At the level of pituitary, no significant change in gene expression levels, or Dio 1 and 2 enzyme activities was observed. In conclusion, both G and D impaired Tg and TH synthesis, but at the same time increased tissue availability of TH in peripheral tissues of Orx middle-aged rats.
    Toxicology and Applied Pharmacology 04/2014; DOI:10.1016/j.taap.2014.04.018 · 3.63 Impact Factor
  • Source
    • "Results of clinical studies with healthy individuals were inconsistent, reporting that isoflavones have significant, mild or no effect on thyroid function (Bitto et al., 2010). However, in a recent randomized double-blind crossover study with subclinically hypothyroid patients receiving soybased phytoestrogens containing G and D for 8 weeks, six of sixty patients developed overt hypothyroidism indicating interference of soy isoflavones with the thyroid hormone axis (Sathyapalan et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that genistein (G) and daidzein (D) administered subcutaneously (10 mg/kg) induce changes in the angio-follicular units of the thyroid gland, reduce concentration of total thyroid hormones (TH) and increase thyrotropin (TSH) in serum of orchidectomized middle-aged (16-month-old) rats. To further investigate these effects, we now examined expression levels of the thyroglobulin (Tg), thyroperoxidase (Tpo), vascular endothelial growth factor A (Vegfa) and deiodinase type 1 (Dio 1) genes in the thyroid; in the pituitary, genes involved in TH feedback control (Tsh β, Dio 1, Dio 2, Trh receptor); and in the liver and kidney, expression of T3-activated genes Dio 1 and Spot 14, as well as transthyretin (Ttr), by quantitative real-time PCR. We also analyzed TPO-immunopositivity and immunofluorescence of T4 bound to Tg, determined thyroid T4 levels and measured deiodinase enzyme activities in examined organs. Decreased expression of Tg and Tpo genes (p < 0.05) correlated with immunohistochemical staining results, and together with decreased serum total T4 levels, indicate decreased Tg and TH synthesis following treatments with both isoflavones. However, expression of Spot 14 (p < 0.05) gene in liver and kidney were up-regulated, and liver Dio 1 expression and activity (p < 0.05) increased. At the level of pituitary, no significant change in gene expression levels, or Dio 1 and 2 enzyme activities was observed. In conclusion, both G and D impaired Tg and TH synthesis, but at the same time increased tissue availability of TH in peripheral tissues of Orx middle-aged rats.
    Toxicology and Applied Pharmacology 01/2014; · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Isolierte Isoflavone werden häufig als Nahrungsergänzungsmittel gegen peri- und postmenopausale Beschwerden angeboten. Diesen aus der Sojapflanze stammenden Pflanzeninhaltsstoffen werden zahlreiche gesundheitliche Effekten nachgesagt wie der Schutz vor Mammakarzinomen, Osteoporose und kardiovaskulären Erkrankungen. Gegenwärtig können jedoch behauptete positive Wirkungen von isolierten Isoflavonen nicht als ausreichend wissenschaftlich belegt angesehen werden. Darüber hinaus wird die Sicherheit dieser Produkte kontrovers diskutiert. Nach Aufnahme hoher Isoflavon-Dosen sind adverse Effekte auf das Brustdrüsengewebe, das Endometrium und die Schilddrüse, Letzteres insbesondere bei bestehendem Jodmangel, nicht auszuschließen. Isoflavone können durch östrogene Effekte möglicherweise einen stimulierenden Einfluss auf bestehende Östrogen-sensitive maligne Zellen aufweisen. Im Fokus der Risikobetrachtung stehen hierbei insbesondere Frauen in und nach der Menopause, da diese die Zielgruppe für Isoflavon-Präparate sind und sie ohnehin ein erhöhtes Brustkrebsrisiko besitzen. Eine längerfristige Gabe von isolierten Isoflavonen insbesondere in höheren Dosierungen ist kritisch zu sehen und sollte zumindest erst nach Aufklärung der Patienten und nicht ohne ärztliche Kontrolle erfolgen.
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 02/2012; 56(2). DOI:10.1007/s00103-012-1604-2 · 1.01 Impact Factor
Show more